FDA Investigator George G Calafactor

George G Calafactor has inspections in 5 countries as of 27 Oct 2023. George G Calafactor has collaborated with a combinined 2738 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
100
Last Inspection Date:
27 Oct 2023
Investigator Role:
FDA Investigator
Redica ID:
100001452
Country:
Denmark, Netherlands, United States of America, Germany, United Kingdom of Great Britain and Northern Ireland
Co-Investigator(s):
A Williams, Alexandra A Carrico, Althea A Williams, Amber M Capello Jones, Amina Bashir, Amy S Graf, Andrew J Garufi, Anthony R Petriella, Art O Czabaniuk, Ashley A Mutawakkil, Barbara Janine Breithaupt, Benjamin J Dastoli, Benjamin J Smith, Bernard P Heidt, Bleta Vuniqi, Bonita S Chester, Brent T Hall, Brian J Mundo, Brian M Campbell, Brian P Putz, Bruce, Bryan J Love, Byungja E Marciante, Calvin K Cook, Candace S Tucker, Caroline H Le, CDR Sean T Creighton, Charles E Frelix, Charles L Zhou, Charles M Spyr, Cheryl A Clausen, Christi L Bellmore, Christina L Bigham, Christine E Kelley, Clifford F Long, Constantin Y Philopoulos, Cynthia L Aycock, Cynthia Li, Danny Tuntevski, Darren S Morgan, David A Paterson, David J Gasparovich, David L Wilson, David P Vanhouten, Dawn C Olenjack, Debara R Reese, Dennis R Hock, Donald W Myrick, Downer, Edward D Mcdonald, Elizabeth J Rigoni, Elizabeth P Kinsella, Ellen J Tave, Emest F Bizjak, Emily J Orban, Eric E Joneson, Eric S Pittman, Erin M Miller, Erma Zaimova, Evelyn Taha, Gary Durbiel Goldner, George Calafactor, Grace E Mcnally, Hans T Meyers, Harperd, Hartman, Jacqueline S Warner, James A Lane, James D Planchon, James E Szelc, James N Rench, James W Plucinski, Jared P Stevens, Jdouglas Park, Jeffrey A Sincek, Jeffrey A Sommers, Jeffrey D Meng, Jesse A Vazquez, Joan A Loreng, John N Woodall, Joneson, Joseph R Strelnik, Julia A Avery, K Gonzlez, Kaarin M Slotte, Kathleen M Adams, Kathryn G Brown, Kathryn M Blackshear, Kayla D Smith, Kelley L Clark, Kimberly Lewandowski Walker, Kinh Q Mac, Kristina Nastovski, Larry K Austin, Latoya A Griffith, Lauren E Burke, Lauren E Sexton, Lauren R Collins, LCDR Anastasia Mpiliafas Brown, Leslie A Paul, Lillie D Witcher, Linda S Jozefiak, Lori S Lawless, Maribeth G Grattan, Maribeth G Niesen, Martha Sullivan Myrick, Meisha R Sampson, Meisha Waters, Melina Lrodriguez Upton, Michael A Moutray, Micmarie Ramos, Monica Cburgos Garcia, Msdap Gonzlezk, Myra K Casey, Neal D Singletary, PhD, Olalere D Fasipe, Patrick B Cummings, Paul E Stein, Perry H Gambrell, Phillip M Pontikos, Pratik S Upadhyay, DDC, Rachael L Cook, Rachel T Evans, Rasha Bamieh, Rebecca E Dombrowski, Richard Jay Tucker, RS, Richard K Vogel, Richard L Rutherford, Robert M Barbosa, Rodney D Combs, Rosanna M Goodrich, Rterry Bolen, Ryan J Benedict, Sanket N Patel, Sargum C Sood, Scott R Izyk, Shana L Williams, Shannon A Gregory, Sherri J Jackson, State Agency, Stephen J Rabe, Sumit Sen, Suyang Qin, Theodore N Sietsema, Thomas A Peter, Tonnie L Carter, Tracey L Siebesma, Tracy R Ball, Travis S Bradley, Twana R Chandler, Vesa Vuniqi, Victoria A Murray, Wanda B Coats, Wenzheng Zhang, William D Tingley, William G Nelson, William R Brubaker, Yehualashet A Gessesse

George G Calafactor's Documents

Publish Date Document Type Title
September, 2003 FDA 483 Response Applied Laboratories, Inc. - Form 483R, 2003-10-01
June, 2003 FDA 483 Response HL Lyons Co - Form 483R, 2004-12-17
September, 2003 EIR Applied Laboratories, Inc. - EIR, 2003-09-30
March, 2000 FDA 483 Ascensia Diabetes Care US, Inc. - Form 483, 2000-03-31
September, 2004 FDA 483 Precision Piece Parts, Inc. - Form 483, 2004-09-21
June, 2001 EIR Ascensia Diabetes Care US, Inc. - EIR, 2001-06-15
September, 2003 FDA 483 Applied Laboratories, Inc. - Form 483, 2003-09-30
June, 2003 FDA 483 HL Lyons Co - Form 483, 2003-06-26
November, 2000 EIR Cantor & Nissel Ltd. - EIR, 2000-11-09
January, 2001 EIR Ascensia Diabetes Care US, Inc. - EIR, 2001-01-10
May, 2000 EIR Ascensia Diabetes Care US, Inc. - EIR, 2000-05-30
June, 2003 FDA 483 Med-Dyne, Inc. - Form 483, 2003-06-19
March, 2000 FDA 483 Response Ascensia Diabetes Care US, Inc. - Form 483R, 2000-04-28
November, 2002 FDA 483 Ascensia Diabetes Care US, Inc. - Form 483, 2002-11-20
March, 2000 EIR Ascensia Diabetes Care US, Inc. - EIR, 2000-03-31

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more